BioSpace News Archive

Ashvattha Therapeutics announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer -based PET tracer, [18F]OP-801, can detect neuroinflammation via activated microglia and macrophages with higher sensitivity than translocator protein 18 kDa [TSPO]-PET, using [18F]GE180, an established and validated PET imaging approach, in a mouse model of Alzheimer’s Disease.

Portage Biotech Inc. today announced financial results for the fiscal year ended March 31, 2022.

CymaBay Therapeutics, Inc. today announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary Cholangitis (PBC).

Akari Therapeutics, Plc, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announced that it is prioritizing two pipeline programs.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the 2022 Alzheimer’s Association International Conference (AAIC).

Candel Therapeutics, Inc. today announced the appointment of three new members to its Board.

Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel drug delivery approaches, today announced the presentation of a study entitled, “Treatment of Alzheimer’s disease by modulation of microglial neuroinflammation by nasal anti-CD3 mAb.”

Gracell Biotechnologies Inc. today announced the appointment of Wendy Li, M.D., as its Chief Medical Officer (CMO).

Corium, Inc., announced today that both strengths of its new once-weekly ADLARITY (donepezil transdermal system) maintain equivalent daily exposure of donepezil when compared to oral formulations of donepezil, along with a favorable overall gastrointestinal (GI) side effect profile, according to trial results reported in a poster (68981) at the Alzheimer’s Association International Conference 2022 in San Diego.

PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022 , by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time.